How Will Clarity’s Cu-64 SARTATE Transform Neuroendocrine Tumour Diagnosis?

middle.news 9:26am on Monday 22nd of December, 2025 AEDT • Healthcare Read Story

How Will Clarity’s Cu-64 SARTATE Transform Neuroendocrine Tumour Diagnosis?

9:26am on Monday 22nd of December, 2025 AEDT Key Points FDA endorses Phase III trial design for Cu-64 SARTATE in neuroendocrine tumours Trial to enroll ~70 patients in a multi-centre, open-label study starting 2026 Previous Phase II data show superior lesion detection versus current standard imaging Cu-64 SARTATE targets somatostatin receptor 2, common in NETs Read Story

middle. Tap to Read Tap the card to read the full analysis about CU6 OPEN ARTICLE